Aerosolized KL4 surfactant improves short-term survival and gas exchange in spontaneously breathing newborn pigs with hydrochloric acid-induced acute lung injury

Pediatric Pulmonology

Volumn 49, Issue 5, 2014, Pages 482-489

  Lampland, Andrea L ^a,b   Wolfson, Marla R ^c   Mazela, Jan ^d,e   Henderson, Christopher ^e   Gregory, Timothy J ^e   Meyers, Patricia ^a   Plumm, Brenda ^a   Worwa, Cathy ^a   Mammel, Mark C ^a,b  

^a CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e Discovery Laboratories Inc   (United States)

Author keywords

acute lung injury; aerosol; CPAP; surfactant

Indexed keywords

HYDROCHLORIC ACID; INTERLEUKIN 8; MYELOPEROXIDASE; SINAPULTIDE; AEROSOL; KL4 SURFACTANT; PEPTIDE; PEROXIDASE;

ACUTE LUNG INJURY; AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL GAS; ARTERIAL PH; ARTICLE; BREATHING RATE; CARBON DIOXIDE TENSION; CONTROLLED STUDY; ENDOTRACHEAL TUBE; GAS EXCHANGE; HEART RATE; LUNG PARENCHYMA; MORPHOMETRICS; NEWBORN; NONHUMAN; OXYGEN SATURATION; OXYGEN TENSION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT TERM SURVIVAL; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG GAS EXCHANGE; METABOLISM; PATHOLOGY; PHARMACOLOGY; RANDOMIZATION; SURVIVAL RATE; SWINE; TOXICITY;

ACUTE LUNG INJURY; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANIMALS, NEWBORN; CONTINUOUS POSITIVE AIRWAY PRESSURE; DISEASE MODELS, ANIMAL; HYDROCHLORIC ACID; INTERLEUKIN-8; LUNG; PEPTIDES; PEROXIDASE; PULMONARY GAS EXCHANGE; RANDOM ALLOCATION; SURVIVAL RATE; SWINE;

EID: 84898596439     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22844     Document Type: Article

References (40)

1. Greenough A,. Expanded use of surfactant replacement therapy. Eur J Pediatr 2000; 159: 635-640.
2. Hallman M, Glumoff V, Ramet M,. Surfactant in respiratory distress syndrome and lung injury. Comp Biochem Physiol A Mol Integr Physiol 2001; 129: 287-294.
3. Committee of Fetus and Newborn. Surfactant replacement therapy for respiratory distress syndrome. Pediatrics 1999; 103: 684-685.
4. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L,. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70: 673-683.
5. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA 3rd, Hudson LD, Maunder RJ, Crim C, Hyers TM,. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-1981.
6. Davidson KG, Bersten AD, Barr HA, Dowling KD, Nicholas TE, Doyle IR,. Endotoxin induces respiratory failure and increases surfactant turnover and respiration independent of alveolocapillary injury in rats. Am J Respir Crit Care Med 2002; 165: 1516-1525.
7. Widner LR, Goodwin SR, Berman LS, Banner MJ, Freid EB, McKee TW,. Artificial surfactant therapy in hydrocarbon-induced lung injury in sheep. Crit Care Med 1996; 24: 1524-1529.
8. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, Jacobs BR, Jefferson LS, Conaway MR, Egan EA,. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293: 470-476.
9. Lewis JF, Veldhuizen R,. The role of exogenous surfactant treatment of acute lung injury. Annu Rev Physiol 2003; 65: 613-642.
10. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L, Bruins P, Steenken EJ, Jeppesen OK, Lachmann B,. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009; 180: 989-994.
11. Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT,. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10: R41.
12. Kribs A,. How best to administer surfactant to VLBW infants ? Arch Dis Child Fetal Neonatal Ed 2011; 96: F238-F240.
13. Marshall TA, Deeder R, Pai S, Berkowitz GP, Austin TL,. Physiologic changes associated with endotracheal intubation in preterm infants. Crit Care Med 1984; 12: 501-503.
14. Newman B, Oh KS,. Iatrogenic tracheobronchial perforation in infants. J Thoracic Imaging 1994; 9: 269-272.
15. Cochrane CG, Revak SD,. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 1991; 254: 566-568.
16. Murdoch E, Kempley ST,. Randomized trial examining cerebral haemodynamics following artificial or animal surfactant. Acta Paediatr 1998; 87: 411-415.
17. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C, Mazela J, Liu G, SELECT and STAR Study Investigators. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 2007; 119: e1361-e1370.
18. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R,. An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv 2010; 23: 303-309.
19. Zimmerman JJ, Akhtar SR, Caldwell E, Rubenfeld GD,. Incidence and outcomes of pediatric acute lung injury. Pediatrics 2009; 124: 87-95.
20. Zimmermann AM, Roberts KD, Lampland AL, Meyers PA, Worwa CT, Plumm B, Pacheco MC, Wolfson MR, Mammel MC,. Improved gas exchange and survival after KL-4 surfactant in newborn pigs with severe acute lung injury. Pediatr Pulmonol 2010; 45: 782-788.
21. Institute of Laboratory Animal Resources. Guidelines for the care and use of laboratory animals (NIH 86-23). Bethesda, MD: National Institutes of Health; 2002.
22. Mazela J, Henderson C,. Ventilation circuit adaptor and proximal aerosol delivery system. 2009 (WO/2009/117422; PCT/US2009/037409).
23. Mazela J, Chmura K, Kulza M, Henderson C, Gregory TJ, Moskal A, Sosnowski TR, Florek E, Kramer L, Keszler M,. Aerosolized albuterol sulfate delivery under neonatal ventilatory conditions: in vitro evaluation of a novel ventilator circuit patient interface connector. J Aerosol Med Pulm D 2013; 26: 1-8.
24. Shashikant BN, Miller TL, Welch RW, Pilon AL, Shaffer TH, Wolfson MR,. Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. J Appl Physiol 2005; 99: 2204-2211.
25. Dijk PH, Heikamp A, Bambang Oetomo S,. Surfactant nebulisation prevents the adverse effects of surfactant therapy on blood pressure and cerebral blood flow in rabbits with severe respiratory failure. Intensive Care Med 1997; 23: 1077-1081.
26. Lewis JF, Tabor B, Ikegami M, Jobe AH, Joseph M, Absolom D,. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. J Appl Physiol 1993; 74: 1256-1264.
27. Lewis JF, Ikegami M, Jobe AH, Absolom D,. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 147: 1364-1370.
28. Lewis JF, Ikegami M, Jobe AH, Tabor B,. Aerosolized surfactant treatment of preterm lambs. J Appl Physiol 1991; 70: 869-876.
29. Lewis J, McCaig L,. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury. Am Rev Respir Dis 1993; 148: 1187-1193.
30. Manalo E, Merritt TA, Amirkhanian JD, Kheiter A,. Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL4 following surface area cycling and addition of fibrinogen. Lung 1997; 175: 225-233.
31. Zhu Y, Miller TL, Chidekel A, Shaffer TH,. KL4 surfactant (Lucinactant) protects human airway epithelium from hyperoxia. Pediatr Res 2008; 64: 154-158.
32. Kinniry P, Pick J, Stephens S, Jain D, Solomides CC, Niven R, Segal R, Christofidou-Solomidou M,. KL4 surfactant prevents hyperoxic and LPS-induced lung injury in mice. Pediatr Pulmonol 2006; 41: 916-928.
33. Johnson M, Rodriguez L, Pearson R, Rairkar M,. KL4 surfactant (Aerosurf) retains surface activity after aerosolization. EPAS 2007; 61: 6292.7.
34. Pearson R, Pippins M, Thomas M, Niven RW, Johnson ME,. Aerosolized KL4 lung surfactant delivered via nCPAP for the treatment of respiratory insufficiency. PAS 2005; 57: 2508.
35. Mazela J, Polin RA,. Aerosol delivery to ventilated newborn infants: historical challenges and new directions. Eur J Pediatr 2011; 170: 433-444.
36. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN,. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf acute respiratory distress syndrome sepsis study group. N Engl J Med 1996; 334: 1417-1421.
37. Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, Hennecke KH, Poets C,. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol 1997; 24: 222-224.
38. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, Schollin J,. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr 2000; 89: 460-464.
39. Mazela J, Merritt TA, Finer NN,. Aerosolized surfactants. Curr Opin Pediatr 2007; 19: 155-162.
40. Becquemin MH, Swift DL, Bouchikhi A, Roy M, Teillac A,. Particle deposition and resistance in the noses of adults and children. Eur Respir J 1991; 4: 694-702.